Jul 18 |
Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
|
Jul 12 |
Amazon (AMZN) Expands AWS Clientele With Exscientia Deal
|
Jul 10 |
Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery
|
Jul 5 |
Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?
|
Jun 19 |
How Much Upside is Left in Exscientia (EXAI)? Wall Street Analysts Think 61.43%
|
Jun 10 |
Exscientia: Too Much Pessimism
|
Jun 6 |
Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology
|
Jun 3 |
Can Exscientia (EXAI) Climb 57.17% to Reach the Level Wall Street Analysts Expect?
|
May 30 |
Exscientia to Present at Upcoming Investor Conferences in June
|
May 25 |
Analysts Are Upgrading Exscientia plc (NASDAQ:EXAI) After Its Latest Results
|